Individualizing dosing of irinotecan
- PMID: 20068075
- DOI: 10.1158/1078-0432.CCR-09-2936
Individualizing dosing of irinotecan
Abstract
Individualized drug dosing is a longstanding goal of clinical pharmacologists. Given the narrow therapeutic index of most anticancer agents, it is plausible that this approach would be of particular value in oncology. Irinotecan is an interesting agent for individualized dosing, given its complex metabolism and increasing knowledge of its pharmacokinetics predictors.
Comment on
-
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.Clin Cancer Res. 2010 Jan 15;16(2):736-42. doi: 10.1158/1078-0432.CCR-09-1526. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068078 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
